Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29832661 | 0.90 | PRMT6 (0.47) | PRMT6P2RY12ADORA1ADORA3ADORA2A | |
| SCHEMBL19128455 | 0.90 | PRMT6 (0.47) | PRMT6P2RY12ADORA1ADORA3ADORA2A | |
| SCHEMBL30446733 | 0.90 | PRMT6 (0.51) | PRMT6P2RY12ADORA1ADORA3ADORA2A | |
| SCHEMBL7032101 | 0.90 | PRMT6 (0.51) | PRMT6P2RY12ADORA1ADORA3ADORA2A | |
| SCHEMBL8937133 | 0.90 | PRMT6 (0.51) | PRMT6P2RY12ADORA1ADORA3ADORA2A | |
| SCHEMBL28359655 | 0.89 | P2RY12 (0.50) | PRMT6P2RY12ADORA1ADORA3ADORA2A | |
| SCHEMBL6402239 | 0.88 | ADORA1 (0.54) | ADORA1ADORA3ADORA2AADORA2BLMNA | |
| SCHEMBL6402244 | 0.88 | ADORA1 (0.54) | ADORA1ADORA3ADORA2AADORA2BLMNA | |
| SCHEMBL30899712 | 0.88 | ADORA1 (0.54) | ADORA1ADORA3ADORA2AADORA2BLMNA | |
| SCHEMBL19128052 | 0.88 | PRMT6 (0.51) | PRMT6P2RY12ADORA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505571-B2 | Compounds and compositions for treating conditions associated with sting activity | INNATE TUMOR IMMUNITY, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20210147467-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | INNATE TUMOR IMMUNITY INC (US) | 2021-05-20 | — | — | US | disclosed |
| US-10961270-B2 | Compounds and compositions for treating conditions associated with sting activity | INNATE TUMOR IMMUNITY, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200165288-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | INNATE TUMOR IMMUNITY INC (US) | 2020-05-28 | — | — | US | disclosed |
| US-10604542-B2 | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | INNATE TUMOR IMMUNITY, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190016750-A1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | Innate Tumoir Immunity, Inc. (US) | 2019-01-17 | — | — | US | disclosed |
| EP-3402801-A1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | Innate Tumor Immunity, Inc. (US) | 2018-11-21 | — | — | EP | disclosed |
| WO-2017123669-A1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | GLICK GARY (US) | 2017-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961270-B2 | Compounds and compositions for treating conditions associated with sting activity | STING1, CGAS, IRF3 | PRMT6 2343/4885P2RY12 588/4885ADORA1 842/4885 |
| US-20200165288-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | PRMT6 2343/4885P2RY12 588/4885ADORA1 842/4885 |
| US-11505571-B2 | Compounds and compositions for treating conditions associated with sting activity | STING1, CGAS, IRF3 | PRMT6 2343/4885P2RY12 588/4885ADORA1 842/4885 |
| US-10604542-B2 | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | STING1, CGAS, IRF3 | PRMT6 1684/4885P2RY12 630/4885ADORA1 1007/4885 |
| US-20190016750-A1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | STING1, CGAS, IRF3 | PRMT6 1684/4885P2RY12 630/4885ADORA1 1007/4885 |
| US-20210147467-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | PRMT6 2343/4885P2RY12 588/4885ADORA1 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.